{
  "supportedLanguages": ["en", "ar"],
  "NutritionalRecommendations": {
    "DietarySystem": {
      "en": "Prioritize whole, unprocessed foods. Focus on high protein, complex carbohydrates, healthy fats, and hydration.",
      "ar": "التركيز على الأطعمة الكاملة غير المصنعة. التركيز على البروتينات عالية والكربوهيدرات المعقدة والدهون الصحية والترطيب."
    },
    "SpecificFoodRecommendations": {
      "MuscleBuilding": {
        "en": "Leucine-rich foods (whey protein, eggs, chicken, fish); post-workout meals combining protein + carbs",
        "ar": "أطعمة غنية بالليوسين (بروتين مصل اللبن، البيض، الدجاج، الأسماك)؛ وجبات ما بعد التمرين تجمع بين البروتين + الكربوهيدرات"
      },
      "FatLoss": {
        "en": "High-fiber foods (vegetables, legumes, whole grains); adequate protein; antioxidant-rich foods (berries, leafy greens); thermogenic foods (green tea, chili peppers)",
        "ar": "أطعمة غنية بالألياف (الخضروات، البقوليات، الحبوب الكاملة)؛ بروتين كافٍ؛ أطعمة غنية بمضادات الأكسدة (التوت، الخضار الورقية)؛ أطعمة مولدة للحرارة (الشاي الأخضر، الفلفل الحار)"
      },
      "OvercomingPlateaus": {
        "en": "Ensure adequate caloric intake; vary food sources; nutrient timing strategies",
        "ar": "ضمان تناول سعرات حرارية كافية؛ تنويع مصادر الطعام؛ استراتيجيات توقيت المغذيات"
      }
    },
    "VitaminRecommendations": [
      {
        "name": {
          "en": "Vitamin D",
          "ar": "فيتامين د"
        },
        "dose": {
          "en": "1000-4000 IU/day (maintenance); up to 5000 IU/day if deficient",
          "ar": "1000-4000 وحدة دولية/يوم (للصيانة)؛ حتى 5000 وحدة دولية/يوم في حالة النقص"
        },
        "usage": {
          "en": "Often taken with fat-containing meal; sun exposure also important",
          "ar": "غالبًا ما تؤخذ مع وجبة تحتوي على الدهون؛ التعرض لأشعة الشمس مهم أيضًا"
        },
        "purpose": {
          "en": "Muscle function, testosterone levels, immune health",
          "ar": "وظيفة العضلات، مستويات هرمون التستوستيرون، صحة المناعة"
        }
      },
      {
        "name": {
          "en": "B Vitamins (B12, B6, Folate)",
          "ar": "فيتامينات ب (ب12، ب6، حمض الفوليك)"
        },
        "dose": {
          "en": "Adequate intake usually achieved through diet",
          "ar": "الكمية الكافية تتحقق عادةً من خلال النظام الغذائي"
        },
        "usage": {
          "en": "Supplement only if deficient",
          "ar": "المكملات فقط في حالة النقص"
        },
        "purpose": {
          "en": "Energy metabolism, red blood cell production",
          "ar": "الأيض الطاقي، إنتاج خلايا الدم الحمراء"
        }
      },
      {
        "name": {
          "en": "Magnesium",
          "ar": "المغنيسيوم"
        },
        "dose": {
          "en": "200-400 mg/day (elemental magnesium)",
          "ar": "200-400 مجم/يوم (مغنيسيوم عنصري)"
        },
        "usage": {
          "en": "Often taken in evening; forms: Glycinate, Citrate, Malate",
          "ar": "غالبًا ما تؤخذ في المساء؛ أشكال: جليسينات، سيترات، مالات"
        },
        "purpose": {
          "en": "Muscle contraction, energy production, sleep quality",
          "ar": "انقباض العضلات، إنتاج الطاقة، جودة النوم"
        }
      },
      {
        "name": {
          "en": "Zinc",
          "ar": "الزنك"
        },
        "dose": {
          "en": "15-30 mg/day",
          "ar": "15-30 مجم/يوم"
        },
        "usage": {
          "en": "Taken with food to reduce nausea",
          "ar": "تؤخذ مع الطعام لتقليل الغثيان"
        },
        "purpose": {
          "en": "Immune function, protein synthesis, hormone production",
          "ar": "وظيفة المناعة، تخليق البروتين، إنتاج الهرمونات"
        }
      }
    ],
    "SupplementRecommendations": [
      {
        "name": {
          "en": "Creatine Monohydrate",
          "ar": "كرياتين أحادي الهيدرات"
        },
        "dose": {
          "en": "3-5 grams per day (loading phase 20g/day for 5-7 days optional)",
          "ar": "3-5 جرام يوميًا (مرحلة التحميل 20 جرام/يوم لمدة 5-7 أيام اختيارية)"
        },
        "usage": {
          "en": "Consistent daily intake; can be taken anytime",
          "ar": "تناول يومي منتظم؛ يمكن تناوله في أي وقت"
        },
        "purpose": {
          "en": "Increases strength, power, lean mass, exercise capacity",
          "ar": "يزيد القوة والقدرة والكتلة الخالية من الدهون والقدرة على التمرين"
        }
      },
      {
        "name": {
          "en": "Beta-Alanine",
          "ar": "بيتا-ألانين"
        },
        "dose": {
          "en": "3.2-6.4 grams per day (split into smaller doses)",
          "ar": "3.2-6.4 جرام يوميًا (مقسمة إلى جرعات أصغر)"
        },
        "usage": {
          "en": "Taken consistently daily",
          "ar": "تؤخذ بانتظام يوميًا"
        },
        "purpose": {
          "en": "Increases muscle carnosine, delays fatigue during high-intensity efforts",
          "ar": "يزيد الكارنوزين العضلي، يؤخر التعب أثناء المجهود الشديد"
        }
      },
      {
        "name": {
          "en": "Caffeine",
          "ar": "الكافيين"
        },
        "dose": {
          "en": "3-6 mg/kg body weight taken 30-60 minutes pre-exercise",
          "ar": "3-6 مجم/كجم من وزن الجسم تؤخذ قبل 30-60 دقيقة من التمرين"
        },
        "usage": {
          "en": "Avoid within 6-8 hours of bedtime",
          "ar": "تجنب تناوله خلال 6-8 ساعات من وقت النوم"
        },
        "purpose": {
          "en": "Improves focus, alertness, endurance, perceived exertion",
          "ar": "يحسن التركيز واليقظة والتحمل والإجهاد المُدرك"
        }
      },
      {
        "name": {
          "en": "Omega-3 Fatty Acids (EPA/DHA)",
          "ar": "أحماض أوميغا-3 الدهنية (EPA/DHA)"
        },
        "dose": {
          "en": "1-3 grams combined EPA+DHA per day",
          "ar": "1-3 جرام مجتمعة من EPA+DHA يوميًا"
        },
        "usage": {
          "en": "Taken with meals containing fat",
          "ar": "تؤخذ مع الوجبات التي تحتوي على الدهون"
        },
        "purpose": {
          "en": "Reduces inflammation, supports muscle protein synthesis, cardiovascular health",
          "ar": "يقلل الالتهابات، يدعم تخليق البروتين العضلي، صحة القلب والأوعية الدموية"
        }
      },
      {
        "name": {
          "en": "Whey Protein",
          "ar": "بروتين مصل اللبن"
        },
        "dose": {
          "en": "20-40g per serving",
          "ar": "20-40 جرام لكل حصة"
        },
        "usage": {
          "en": "Mixed with water or milk; consume within 1-2 hours post-workout",
          "ar": "يخلط بالماء أو الحليب؛ يستهلك خلال 1-2 ساعة بعد التمرين"
        },
        "purpose": {
          "en": "Convenient protein source to support muscle protein synthesis",
          "ar": "مصدر بروتين مريح لدعم تخليق البروتين العضلي"
        }
      }
    ]
  },
  "ExerciseRecommendations": {
    "ResistanceTraining": {
      "focus": {
        "en": "Compound movements (squats, deadlifts, bench press, overhead press, rows, pull-ups)",
        "ar": "حركات مركبة (القرفصاء، الرفعة الميتة، ضغط الصدر، الضغط فوق الرأس، صف الذراعين، سحب الجسم)"
      },
      "progressiveOverload": {
        "en": "Systematically increase weight, reps, sets, reduce rest time, improve technique",
        "ar": "زيادة الوزن والتكرارات والمجموعات بشكل منهجي، تقليل وقت الراحة، تحسين التقنية"
      },
      "intensity": {
        "en": "Train close to muscular failure (1-3 reps in reserve)",
        "ar": "التدريب قرب فشل العضلات (1-3 تكرارات احتياطية)"
      },
      "volume": {
        "en": "Beginners: 10-15 sets/week/muscle group; Intermediate/Advanced: 15-25+ sets/week/muscle group",
        "ar": "المبتدئون: 10-15 مجموعة/أسبوع/مجموعة عضلية؛ المتوسطون/المتقدمون: 15-25+ مجموعة/أسبوع/مجموعة عضلية"
      },
      "frequency": {
        "en": "Train each muscle group 2-4 times per week",
        "ar": "تدريب كل مجموعة عضلية 2-4 مرات في الأسبوع"
      },
      "technique": {
        "en": "Prioritize perfect form over weight",
        "ar": "إعطاء الأولوية للشكل المثالي على الوزن"
      }
    },
    "CardiovascularExercise": {
      "purpose": {
        "en": "Enhance recovery, improve cardiovascular health, increase calorie expenditure",
        "ar": "تعزيز التعافي، تحسين صحة القلب والأوعية الدموية، زيادة إنفاق السعرات الحرارية"
      },
      "types": [
        {
          "name": {
            "en": "Moderate-Intensity Steady State (MISS)",
            "ar": "حالة ثابتة الشدة المعتدلة (MISS)"
          },
          "description": {
            "en": "Brisk walking, jogging, cycling, elliptical",
            "ar": "المشي السريع، الركض، ركوب الدراجات، الجهاز الإهليلجي"
          },
          "duration": {
            "en": "20-60 minutes",
            "ar": "20-60 دقيقة"
          },
          "frequency": {
            "en": "2-5 times/week",
            "ar": "2-5 مرات/أسبوع"
          }
        },
        {
          "name": {
            "en": "High-Intensity Interval Training (HIIT)",
            "ar": "التدريب الفاصل عالي الشدة (HIIT)"
          },
          "description": {
            "en": "Short bursts (10-60 sec) of max effort followed by recovery periods",
            "ar": "انفجارات قصيرة (10-60 ثانية) من أقصى جهد تليها فترات راحة"
          },
          "duration": {
            "en": "10-25 minutes total",
            "ar": "10-25 دقيقة إجمالاً"
          },
          "frequency": {
            "en": "1-3 times/week",
            "ar": "1-3 مرات/أسبوع"
          }
        }
      ]
    },
    "RestAndRecovery": {
      "sleep": {
        "en": "Aim for 7-9 hours of quality sleep per night",
        "ar": "الاستهداف لمدة 7-9 ساعات من النوم الجيد كل ليلة"
      },
      "restDays": {
        "en": "Minimum 1-2 full rest days per week",
        "ar": "حد أدنى 1-2 يوم راحة كاملة في الأسبوع"
      },
      "deloads": {
        "en": "Schedule deliberate reduction in volume (40-60%) every 4-12 weeks",
        "ar": "جدولة تخفيض متعمد في الحجم (40-60%) كل 4-12 أسبوعًا"
      }
    },
    "ScenarioSpecificAdjustments": {
      "slowMuscleBuilding": {
        "en": "Prioritize progressive overload; ensure sufficient volume/frequency; optimize protein/sleep",
        "ar": "إعطاء الأولوية للحمل الزائد التدريجي؛ ضمان حجم/تكرار كافٍ؛ تحسين البروتين/النوم"
      },
      "slowFatBurning": {
        "en": "Create sustainable caloric deficit; increase NEAT; incorporate HIIT; ensure adequate sleep",
        "ar": "إنشاء عجز حراري مستدام؛ زيادة النشاط غير التمريني (NEAT)؛ دمج HIIT؛ ضمان نوم كافٍ"
      },
      "stagnantMuscleMass": {
        "en": "Re-evaluate program; focus on time under tension; check recovery; consider deload",
        "ar": "إعادة تقييم البرنامج؛ التركيز على وقت التوتر؛ فحص التعافي؛ النظر في التخفيف"
      },
      "beginnerPlateau": {
        "en": "Master form; increase reps then weight; ensure consistency",
        "ar": "إتقان الشكل؛ زيادة التكرارات ثم الوزن؛ ضمان الاستمرارية"
      },
      "advancedPlateau": {
        "en": "Implement periodization; vary training variables; employ advanced techniques; ensure optimal recovery",
        "ar": "تنفيذ التدوير الدوري؛ تنويع متغيرات التدريب؛ استخدام تقنيات متقدمة؛ ضمان تعافي مثالي"
      }
    }
  },
  "MedicationRecommendations": {
    "disclaimer": {
      "en": "Medications should ONLY be considered after thorough medical evaluation and under strict medical supervision",
      "ar": "يجب النظر في الأدوية فقط بعد تقييم طبي شامل وتحت إشراف طبي صارم"
    },
    "potentialMedications": [
      {
        "name": {
          "en": "Testosterone Replacement Therapy (TRT)",
          "ar": "العلاج البديل بالتستوستيرون (TRT)"
        },
        "for": {
          "en": "Men with clinically diagnosed hypogonadism",
          "ar": "الرجال الذين تم تشخيصهم إكلينيكيًا بقصور الغدد التناسلية"
        },
        "dose": {
          "en": "Highly individualized (e.g., 50-200 mg testosterone enanthate/cypionate IM every 1-2 weeks)",
          "ar": "شخصي للغاية (مثال: 50-200 مجم تستوستيرون إينانثات/سيبيونات عضلي كل 1-2 أسبوع)"
        },
        "usage": {
          "en": "Requires lifelong monitoring (blood tests)",
          "ar": "يتطلب مراقبة مدى الحياة (فحوصات دم)"
        },
        "notFor": {
          "en": "Performance enhancement in individuals with normal levels",
          "ar": "تحسين الأداء لدى الأفراد ذوي المستويات الطبيعية"
        }
      },
      {
        "name": {
          "en": "Thyroid Hormone (Levothyroxine)",
          "ar": "هرمون الغدة الدرقية (ليفوثيروكسين)"
        },
        "for": {
          "en": "Individuals with clinically diagnosed hypothyroidism",
          "ar": "الأفراد الذين تم تشخيصهم إكلينيكيًا بقصور الغدة الدرقية"
        },
        "dose": {
          "en": "Titrated based on blood tests (e.g., starting 25-50 mcg/day)",
          "ar": "يضبط بناءً على فحوصات الدم (مثال: البدء بـ 25-50 ميكروغرام/يوم)"
        },
        "usage": {
          "en": "Taken daily on empty stomach",
          "ar": "يؤخذ يوميًا على معدة فارغة"
        },
        "notFor": {
          "en": "Weight loss in euthyroid individuals",
          "ar": "فقدان الوزن لدى الأفراد ذوي وظيفة الغدة الدرقية الطبيعية"
        }
      },
      {
        "name": {
          "en": "Metformin",
          "ar": "ميتفورمين"
        },
        "for": {
          "en": "Type 2 Diabetes or Prediabetes with insulin resistance",
          "ar": "مرض السكري من النوع 2 أو ما قبل السكري مع مقاومة الأنسولين"
        },
        "dose": {
          "en": "Start low (500 mg once daily), increase gradually (e.g., to 1000 mg twice daily)",
          "ar": "ابدأ بجرعة منخفضة (500 مجم مرة واحدة يوميًا)، زد تدريجيًا (مثال: إلى 1000 مجم مرتين يوميًا)"
        },
        "usage": {
          "en": "Taken with meals",
          "ar": "يؤخذ مع الوجبات"
        },
        "notFor": {
          "en": "General weight loss or performance enhancement",
          "ar": "فقدان الوزن العام أو تحسين الأداء"
        }
      },
      {
        "name": {
          "en": "Stimulants (Phentermine)",
          "ar": "المحفزات (فينترمين)"
        },
        "for": {
          "en": "Short-term management of obesity under strict medical supervision",
          "ar": "إدارة السمنة قصيرة المدى تحت إشراف طبي صارم"
        },
        "dose": {
          "en": "Typically 15-37.5 mg once daily in morning",
          "ar": "عادة 15-37.5 مجم مرة واحدة يوميًا في الصباح"
        },
        "usage": {
          "en": "Appetite suppressant",
          "ar": "مثبط للشهية"
        },
        "notFor": {
          "en": "Performance enhancement or non-obese individuals",
          "ar": "تحسين الأداء أو الأفراد غير البدناء"
        }
      }
    ],
    "medicalSupervisionRequirements": [
      {
        "en": "Comprehensive Diagnosis (bloodwork, medical history, physical exam)",
        "ar": "تشخيص شامل (فحوصات دم، التاريخ الطبي، الفحص البدني)"
      },
      {
        "en": "Risk-Benefit Assessment",
        "ar": "تقييم المخاطر والفوائد"
      },
      {
        "en": "Individualized Dosing & Monitoring",
        "ar": "الجرعات الشخصية والمراقبة"
      },
      {
        "en": "Lifestyle Foundation",
        "ar": "أساسيات نمط الحياة"
      },
      {
        "en": "Legal & Ethical Prescribing",
        "ar": "الوصفة الطبية القانونية والأخلاقية"
      }
    ]
  },
  "ScenarioSpecificApproach": [
    {
      "scenario": {
        "en": "Slow Muscle Building",
        "ar": "بناء عضلي بطيء"
      },
      "keyNutritionalFocus": {
        "en": "High Protein (1.6-2.2g/kg), Caloric Surplus, Creatine",
        "ar": "بروتين عالٍ (1.6-2.2جم/كجم)، فائض حراري، كرياتين"
      },
      "keyExerciseFocus": {
        "en": "Progressive Overload, Sufficient Volume/Frequency",
        "ar": "الحمل الزائد التدريجي، حجم/تكرار كافٍ"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out hypogonadism (Testosterone levels)",
        "ar": "استبعاد قصور الغدد التناسلية (مستويات التستوستيرون)"
      }
    },
    {
      "scenario": {
        "en": "Slow Fat Burning",
        "ar": "حرق دهون بطيء"
      },
      "keyNutritionalFocus": {
        "en": "Caloric Deficit, High Protein, High Fiber, NEAT",
        "ar": "عجز حراري، بروتين عالٍ، ألياف عالية، نشاط غير تمريني (NEAT)"
      },
      "keyExerciseFocus": {
        "en": "Resistance Training + HIIT + MISS, Increase Daily Activity",
        "ar": "التدريب المقاوم + HIIT + MISS، زيادة النشاط اليومي"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out hypothyroidism, insulin resistance",
        "ar": "استبعاد قصور الغدة الدرقية، مقاومة الأنسولين"
      }
    },
    {
      "scenario": {
        "en": "Stubborn Fat",
        "ar": "الدهون العنيدة"
      },
      "keyNutritionalFocus": {
        "en": "Sustained Deficit, High Protein, Manage Stress/Sleep",
        "ar": "عجز مستدام، بروتين عالٍ، إدارة التوتر/النوم"
      },
      "keyExerciseFocus": {
        "en": "Consistent Deficit + Resistance Training + HIIT",
        "ar": "عجز ثابت + تدريب مقاوم + HIIT"
      },
      "potentialMedicalConsiderations": {
        "en": "Address underlying insulin resistance",
        "ar": "معالجة مقاومة الأنسولين الكامنة"
      }
    },
    {
      "scenario": {
        "en": "Stagnant Muscle Mass",
        "ar": "ركود الكتلة العضلية"
      },
      "keyNutritionalFocus": {
        "en": "Ensure Adequate Calories/Protein, Nutrient Timing",
        "ar": "ضمان سعرات حرارية/بروتين كافية، توقيت المغذيات"
      },
      "keyExerciseFocus": {
        "en": "Re-evaluate Program: Form, Volume, Intensity, Recovery",
        "ar": "إعادة تقييم البرنامج: الشكل، الحجم، الشدة، التعافي"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out hormonal imbalances",
        "ar": "استبعاد الاختلالات الهرمونية"
      }
    },
    {
      "scenario": {
        "en": "Beginner Weight Plateau",
        "ar": "هضبة وزن المبتدئين"
      },
      "keyNutritionalFocus": {
        "en": "Master Form, Increase Reps then Weight, Protein",
        "ar": "إتقان الشكل، زيادة التكرارات ثم الوزن، البروتين"
      },
      "keyExerciseFocus": {
        "en": "Focus on Technique & Progressive Reps, Consistency",
        "ar": "التركيز على التقنية والتكرارات التدريجية، الاستمرارية"
      },
      "potentialMedicalConsiderations": {
        "en": "Rarely needed; focus on fundamentals",
        "ar": "نادرًا ما يحتاج؛ التركيز على الأساسيات"
      }
    },
    {
      "scenario": {
        "en": "Advanced Weight Plateau",
        "ar": "هضبة وزن المتقدمين"
      },
      "keyNutritionalFocus": {
        "en": "Optimize Nutrition Timing/Recovery, Creatine, Beta-Alanine",
        "ar": "تحسين توقيت التغذية/التعافي، الكرياتين، بيتا-ألانين"
      },
      "keyExerciseFocus": {
        "en": "Periodization, Advanced Overload Techniques, Deloads",
        "ar": "التدوير الدوري، تقنيات الحمل الزائد المتقدمة، التخفيف"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out overtraining syndrome, hormonal issues",
        "ar": "استبعاد متلازمة الإفراط في التدريب، المشاكل الهرمونية"
      }
    }
  ],
  "References": [
    "Morton, R. W., et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine, 52(6), 376–384. https://bjsm.bmj.com/content/52/6/376",
    "Kreider, R. B., et al. (2017). International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition, 14(1), 18. https://jissn.biomedcentral.com/articles/10.1186/s12970-017-0173-z",
    "Saunders, B., et al. (2012). Beta-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis. Amino Acids, 43(1), 25–37. https://link.springer.com/article/10.1007/s00726-011-1200-z",
    "Southward, K., et al. (2022). The effect of caffeine on exercise performance: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 19(1), 63. https://jissn.biomedcentral.com/articles/10.1186/s12970-022-00832-8",
    "Schoenfeld, B. J., et al. (2017). Resistance Training Recommendations to Maximize Muscle Hypertrophy: An Evidence-Based Approach. Strength and Conditioning Journal, 39(5), 34–47. https://journals.lww.com/nsca-scj/fulltext/2017/10000/resistance_training_recommendations_to_maximize.5.aspx",
    "Clark, J. E. (2018). Diet, exercise or diet with exercise: comparing the effectiveness of treatment options for weight-loss and weight-loss maintenance. Journal of Human Nutrition and Dietetics, 31(3), 329–339. https://onlinelibrary.wiley.com/doi/full/10.1111/jhn.12532",
    "Bhasin, S., et al. (2018). Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://academic.oup.com/jcem/article/103/5/1715/4929253",
    "Garber, J. R., et al. (2012). Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22(12), 1200–1235. https://www.liebertpub.com/doi/10.1089/thy.2012.0205",
    "Fullagar, H. H. K., et al. (2015). The role of sleep in athletic performance. Frontiers in Physiology, 6, 142. https://www.frontiersin.org/articles/10.3389/fphys.2015.00142/full"
  ]
}
{
  "supportedLanguages": ["en", "ar"],
  "NutritionalRecommendations": {
    "DietarySystem": {
      "en": "Prioritize whole, unprocessed foods. Focus on high protein, complex carbohydrates, healthy fats, and hydration.",
      "ar": "التركيز على الأطعمة الكاملة غير المصنعة. التركيز على البروتينات عالية والكربوهيدرات المعقدة والدهون الصحية والترطيب."
    },
    "SpecificFoodRecommendations": {
      "MuscleBuilding": {
        "en": "Leucine-rich foods (whey protein, eggs, chicken, fish); post-workout meals combining protein + carbs",
        "ar": "أطعمة غنية بالليوسين (بروتين مصل اللبن، البيض، الدجاج، الأسماك)؛ وجبات ما بعد التمرين تجمع بين البروتين + الكربوهيدرات"
      },
      "FatLoss": {
        "en": "High-fiber foods (vegetables, legumes, whole grains); adequate protein; antioxidant-rich foods (berries, leafy greens); thermogenic foods (green tea, chili peppers)",
        "ar": "أطعمة غنية بالألياف (الخضروات، البقوليات، الحبوب الكاملة)؛ بروتين كافٍ؛ أطعمة غنية بمضادات الأكسدة (التوت، الخضار الورقية)؛ أطعمة مولدة للحرارة (الشاي الأخضر، الفلفل الحار)"
      },
      "OvercomingPlateaus": {
        "en": "Ensure adequate caloric intake; vary food sources; nutrient timing strategies",
        "ar": "ضمان تناول سعرات حرارية كافية؛ تنويع مصادر الطعام؛ استراتيجيات توقيت المغذيات"
      }
    },
    "VitaminRecommendations": [
      {
        "name": {
          "en": "Vitamin D",
          "ar": "فيتامين د"
        },
        "dose": {
          "en": "1000-4000 IU/day (maintenance); up to 5000 IU/day if deficient",
          "ar": "1000-4000 وحدة دولية/يوم (للصيانة)؛ حتى 5000 وحدة دولية/يوم في حالة النقص"
        },
        "usage": {
          "en": "Often taken with fat-containing meal; sun exposure also important",
          "ar": "غالبًا ما تؤخذ مع وجبة تحتوي على الدهون؛ التعرض لأشعة الشمس مهم أيضًا"
        },
        "purpose": {
          "en": "Muscle function, testosterone levels, immune health",
          "ar": "وظيفة العضلات، مستويات هرمون التستوستيرون، صحة المناعة"
        }
      },
      {
        "name": {
          "en": "B Vitamins (B12, B6, Folate)",
          "ar": "فيتامينات ب (ب12، ب6، حمض الفوليك)"
        },
        "dose": {
          "en": "Adequate intake usually achieved through diet",
          "ar": "الكمية الكافية تتحقق عادةً من خلال النظام الغذائي"
        },
        "usage": {
          "en": "Supplement only if deficient",
          "ar": "المكملات فقط في حالة النقص"
        },
        "purpose": {
          "en": "Energy metabolism, red blood cell production",
          "ar": "الأيض الطاقي، إنتاج خلايا الدم الحمراء"
        }
      },
      {
        "name": {
          "en": "Magnesium",
          "ar": "المغنيسيوم"
        },
        "dose": {
          "en": "200-400 mg/day (elemental magnesium)",
          "ar": "200-400 مجم/يوم (مغنيسيوم عنصري)"
        },
        "usage": {
          "en": "Often taken in evening; forms: Glycinate, Citrate, Malate",
          "ar": "غالبًا ما تؤخذ في المساء؛ أشكال: جليسينات، سيترات، مالات"
        },
        "purpose": {
          "en": "Muscle contraction, energy production, sleep quality",
          "ar": "انقباض العضلات، إنتاج الطاقة، جودة النوم"
        }
      },
      {
        "name": {
          "en": "Zinc",
          "ar": "الزنك"
        },
        "dose": {
          "en": "15-30 mg/day",
          "ar": "15-30 مجم/يوم"
        },
        "usage": {
          "en": "Taken with food to reduce nausea",
          "ar": "تؤخذ مع الطعام لتقليل الغثيان"
        },
        "purpose": {
          "en": "Immune function, protein synthesis, hormone production",
          "ar": "وظيفة المناعة، تخليق البروتين، إنتاج الهرمونات"
        }
      }
    ],
    "SupplementRecommendations": [
      {
        "name": {
          "en": "Creatine Monohydrate",
          "ar": "كرياتين أحادي الهيدرات"
        },
        "dose": {
          "en": "3-5 grams per day (loading phase 20g/day for 5-7 days optional)",
          "ar": "3-5 جرام يوميًا (مرحلة التحميل 20 جرام/يوم لمدة 5-7 أيام اختيارية)"
        },
        "usage": {
          "en": "Consistent daily intake; can be taken anytime",
          "ar": "تناول يومي منتظم؛ يمكن تناوله في أي وقت"
        },
        "purpose": {
          "en": "Increases strength, power, lean mass, exercise capacity",
          "ar": "يزيد القوة والقدرة والكتلة الخالية من الدهون والقدرة على التمرين"
        }
      },
      {
        "name": {
          "en": "Beta-Alanine",
          "ar": "بيتا-ألانين"
        },
        "dose": {
          "en": "3.2-6.4 grams per day (split into smaller doses)",
          "ar": "3.2-6.4 جرام يوميًا (مقسمة إلى جرعات أصغر)"
        },
        "usage": {
          "en": "Taken consistently daily",
          "ar": "تؤخذ بانتظام يوميًا"
        },
        "purpose": {
          "en": "Increases muscle carnosine, delays fatigue during high-intensity efforts",
          "ar": "يزيد الكارنوزين العضلي، يؤخر التعب أثناء المجهود الشديد"
        }
      },
      {
        "name": {
          "en": "Caffeine",
          "ar": "الكافيين"
        },
        "dose": {
          "en": "3-6 mg/kg body weight taken 30-60 minutes pre-exercise",
          "ar": "3-6 مجم/كجم من وزن الجسم تؤخذ قبل 30-60 دقيقة من التمرين"
        },
        "usage": {
          "en": "Avoid within 6-8 hours of bedtime",
          "ar": "تجنب تناوله خلال 6-8 ساعات من وقت النوم"
        },
        "purpose": {
          "en": "Improves focus, alertness, endurance, perceived exertion",
          "ar": "يحسن التركيز واليقظة والتحمل والإجهاد المُدرك"
        }
      },
      {
        "name": {
          "en": "Omega-3 Fatty Acids (EPA/DHA)",
          "ar": "أحماض أوميغا-3 الدهنية (EPA/DHA)"
        },
        "dose": {
          "en": "1-3 grams combined EPA+DHA per day",
          "ar": "1-3 جرام مجتمعة من EPA+DHA يوميًا"
        },
        "usage": {
          "en": "Taken with meals containing fat",
          "ar": "تؤخذ مع الوجبات التي تحتوي على الدهون"
        },
        "purpose": {
          "en": "Reduces inflammation, supports muscle protein synthesis, cardiovascular health",
          "ar": "يقلل الالتهابات، يدعم تخليق البروتين العضلي، صحة القلب والأوعية الدموية"
        }
      },
      {
        "name": {
          "en": "Whey Protein",
          "ar": "بروتين مصل اللبن"
        },
        "dose": {
          "en": "20-40g per serving",
          "ar": "20-40 جرام لكل حصة"
        },
        "usage": {
          "en": "Mixed with water or milk; consume within 1-2 hours post-workout",
          "ar": "يخلط بالماء أو الحليب؛ يستهلك خلال 1-2 ساعة بعد التمرين"
        },
        "purpose": {
          "en": "Convenient protein source to support muscle protein synthesis",
          "ar": "مصدر بروتين مريح لدعم تخليق البروتين العضلي"
        }
      }
    ]
  },
  "ExerciseRecommendations": {
    "ResistanceTraining": {
      "focus": {
        "en": "Compound movements (squats, deadlifts, bench press, overhead press, rows, pull-ups)",
        "ar": "حركات مركبة (القرفصاء، الرفعة الميتة، ضغط الصدر، الضغط فوق الرأس، صف الذراعين، سحب الجسم)"
      },
      "progressiveOverload": {
        "en": "Systematically increase weight, reps, sets, reduce rest time, improve technique",
        "ar": "زيادة الوزن والتكرارات والمجموعات بشكل منهجي، تقليل وقت الراحة، تحسين التقنية"
      },
      "intensity": {
        "en": "Train close to muscular failure (1-3 reps in reserve)",
        "ar": "التدريب قرب فشل العضلات (1-3 تكرارات احتياطية)"
      },
      "volume": {
        "en": "Beginners: 10-15 sets/week/muscle group; Intermediate/Advanced: 15-25+ sets/week/muscle group",
        "ar": "المبتدئون: 10-15 مجموعة/أسبوع/مجموعة عضلية؛ المتوسطون/المتقدمون: 15-25+ مجموعة/أسبوع/مجموعة عضلية"
      },
      "frequency": {
        "en": "Train each muscle group 2-4 times per week",
        "ar": "تدريب كل مجموعة عضلية 2-4 مرات في الأسبوع"
      },
      "technique": {
        "en": "Prioritize perfect form over weight",
        "ar": "إعطاء الأولوية للشكل المثالي على الوزن"
      }
    },
    "CardiovascularExercise": {
      "purpose": {
        "en": "Enhance recovery, improve cardiovascular health, increase calorie expenditure",
        "ar": "تعزيز التعافي، تحسين صحة القلب والأوعية الدموية، زيادة إنفاق السعرات الحرارية"
      },
      "types": [
        {
          "name": {
            "en": "Moderate-Intensity Steady State (MISS)",
            "ar": "حالة ثابتة الشدة المعتدلة (MISS)"
          },
          "description": {
            "en": "Brisk walking, jogging, cycling, elliptical",
            "ar": "المشي السريع، الركض، ركوب الدراجات، الجهاز الإهليلجي"
          },
          "duration": {
            "en": "20-60 minutes",
            "ar": "20-60 دقيقة"
          },
          "frequency": {
            "en": "2-5 times/week",
            "ar": "2-5 مرات/أسبوع"
          }
        },
        {
          "name": {
            "en": "High-Intensity Interval Training (HIIT)",
            "ar": "التدريب الفاصل عالي الشدة (HIIT)"
          },
          "description": {
            "en": "Short bursts (10-60 sec) of max effort followed by recovery periods",
            "ar": "انفجارات قصيرة (10-60 ثانية) من أقصى جهد تليها فترات راحة"
          },
          "duration": {
            "en": "10-25 minutes total",
            "ar": "10-25 دقيقة إجمالاً"
          },
          "frequency": {
            "en": "1-3 times/week",
            "ar": "1-3 مرات/أسبوع"
          }
        }
      ]
    },
    "RestAndRecovery": {
      "sleep": {
        "en": "Aim for 7-9 hours of quality sleep per night",
        "ar": "الاستهداف لمدة 7-9 ساعات من النوم الجيد كل ليلة"
      },
      "restDays": {
        "en": "Minimum 1-2 full rest days per week",
        "ar": "حد أدنى 1-2 يوم راحة كاملة في الأسبوع"
      },
      "deloads": {
        "en": "Schedule deliberate reduction in volume (40-60%) every 4-12 weeks",
        "ar": "جدولة تخفيض متعمد في الحجم (40-60%) كل 4-12 أسبوعًا"
      }
    },
    "ScenarioSpecificAdjustments": {
      "slowMuscleBuilding": {
        "en": "Prioritize progressive overload; ensure sufficient volume/frequency; optimize protein/sleep",
        "ar": "إعطاء الأولوية للحمل الزائد التدريجي؛ ضمان حجم/تكرار كافٍ؛ تحسين البروتين/النوم"
      },
      "slowFatBurning": {
        "en": "Create sustainable caloric deficit; increase NEAT; incorporate HIIT; ensure adequate sleep",
        "ar": "إنشاء عجز حراري مستدام؛ زيادة النشاط غير التمريني (NEAT)؛ دمج HIIT؛ ضمان نوم كافٍ"
      },
      "stagnantMuscleMass": {
        "en": "Re-evaluate program; focus on time under tension; check recovery; consider deload",
        "ar": "إعادة تقييم البرنامج؛ التركيز على وقت التوتر؛ فحص التعافي؛ النظر في التخفيف"
      },
      "beginnerPlateau": {
        "en": "Master form; increase reps then weight; ensure consistency",
        "ar": "إتقان الشكل؛ زيادة التكرارات ثم الوزن؛ ضمان الاستمرارية"
      },
      "advancedPlateau": {
        "en": "Implement periodization; vary training variables; employ advanced techniques; ensure optimal recovery",
        "ar": "تنفيذ التدوير الدوري؛ تنويع متغيرات التدريب؛ استخدام تقنيات متقدمة؛ ضمان تعافي مثالي"
      }
    }
  },
  "MedicationRecommendations": {
    "disclaimer": {
      "en": "Medications should ONLY be considered after thorough medical evaluation and under strict medical supervision. Many listed substances have significant risks and legal restrictions.",
      "ar": "يجب النظر في الأدوية فقط بعد تقييم طبي شامل وتحت إشراف طبي صارم. العديد من المواد المذكورة لها مخاطر كبيرة وقيود قانونية."
    },
    "potentialMedications": [
      {
        "name": {
          "en": "Testosterone Replacement Therapy (TRT)",
          "ar": "العلاج البديل بالتستوستيرون (TRT)"
        },
        "for": {
          "en": "Men with clinically diagnosed hypogonadism",
          "ar": "الرجال الذين تم تشخيصهم إكلينيكيًا بقصور الغدد التناسلية"
        },
        "dose": {
          "en": "Highly individualized (e.g., 50-200 mg testosterone enanthate/cypionate IM every 1-2 weeks)",
          "ar": "شخصي للغاية (مثال: 50-200 مجم تستوستيرون إينانثات/سيبيونات عضلي كل 1-2 أسبوع)"
        },
        "usage": {
          "en": "Requires lifelong monitoring (blood tests)",
          "ar": "يتطلب مراقبة مدى الحياة (فحوصات دم)"
        },
        "notFor": {
          "en": "Performance enhancement in individuals with normal levels",
          "ar": "تحسين الأداء لدى الأفراد ذوي المستويات الطبيعية"
        },
        "warnings": {
          "en": "May cause polycythemia, acne, gynecomastia, infertility. Controlled substance in many countries.",
          "ar": "قد يسبب كثرة الحمراء، حب الشباب، تثدي الرجل، العقم. مادة خاضعة للرقابة في العديد من البلدان."
        }
      },
      {
        "name": {
          "en": "Thyroid Hormone (Levothyroxine)",
          "ar": "هرمون الغدة الدرقية (ليفوثيروكسين)"
        },
        "for": {
          "en": "Individuals with clinically diagnosed hypothyroidism",
          "ar": "الأفراد الذين تم تشخيصهم إكلينيكيًا بقصور الغدة الدرقية"
        },
        "dose": {
          "en": "Titrated based on blood tests (e.g., starting 25-50 mcg/day)",
          "ar": "يضبط بناءً على فحوصات الدم (مثال: البدء بـ 25-50 ميكروغرام/يوم)"
        },
        "usage": {
          "en": "Taken daily on empty stomach",
          "ar": "يؤخذ يوميًا على معدة فارغة"
        },
        "notFor": {
          "en": "Weight loss in euthyroid individuals",
          "ar": "فقدان الوزن لدى الأفراد ذوي وظيفة الغدة الدرقية الطبيعية"
        },
        "warnings": {
          "en": "Overdose can cause hyperthyroidism symptoms (anxiety, palpitations, weight loss). Requires regular blood monitoring.",
          "ar": "الجرعة الزائدة يمكن أن تسبب أعراض فرط نشاط الغدة الدرقية (القلق، خفقان القلب، فقدان الوزن). تتطلب مراقبة دم منتظمة."
        }
      },
      {
        "name": {
          "en": "Metformin",
          "ar": "ميتفورمين"
        },
        "for": {
          "en": "Type 2 Diabetes or Prediabetes with insulin resistance",
          "ar": "مرض السكري من النوع 2 أو ما قبل السكري مع مقاومة الأنسولين"
        },
        "dose": {
          "en": "Start low (500 mg once daily), increase gradually (e.g., to 1000 mg twice daily)",
          "ar": "ابدأ بجرعة منخفضة (500 مجم مرة واحدة يوميًا)، زد تدريجيًا (مثال: إلى 1000 مجم مرتين يوميًا)"
        },
        "usage": {
          "en": "Taken with meals",
          "ar": "يؤخذ مع الوجبات"
        },
        "notFor": {
          "en": "General weight loss or performance enhancement",
          "ar": "فقدان الوزن العام أو تحسين الأداء"
        },
        "warnings": {
          "en": "Common GI side effects (diarrhea, nausea). Can cause vitamin B12 deficiency with long-term use.",
          "ar": "آثار جانبية معوية شائعة (إسهال، غثيان). يمكن أن يسبب نقص فيتامين B12 مع الاستخدام طويل الأمد."
        }
      },
      {
        "name": {
          "en": "Stimulants (Phentermine)",
          "ar": "المحفزات (فينترمين)"
        },
        "for": {
          "en": "Short-term management of obesity under strict medical supervision",
          "ar": "إدارة السمنة قصيرة المدى تحت إشراف طبي صارم"
        },
        "dose": {
          "en": "Typically 15-37.5 mg once daily in morning",
          "ar": "عادة 15-37.5 مجم مرة واحدة يوميًا في الصباح"
        },
        "usage": {
          "en": "Appetite suppressant",
          "ar": "مثبط للشهية"
        },
        "notFor": {
          "en": "Performance enhancement or non-obese individuals",
          "ar": "تحسين الأداء أو الأفراد غير البدناء"
        },
        "warnings": {
          "en": "Controlled substance with abuse potential. Side effects include increased heart rate, hypertension, insomnia. Not recommended >12 weeks.",
          "ar": "مادة خاضعة للرقابة مع إمكانية الإساءة. الآثار الجانبية تشمل زيادة معدل ضربات القلب، ارتفاع ضغط الدم، الأرق. لا يوصى به لأكثر من 12 أسبوعًا."
        }
      },
      {
        "name": {
          "en": "Growth Hormone (GH)",
          "ar": "هرمون النمو (GH)"
        },
        "for": {
          "en": "Medically diagnosed GH deficiency; rarely for severe wasting conditions",
          "ar": "نقص هرمون النمو تشخيص طبي؛ نادرًا لحالات الهزال الشديدة"
        },
        "dose": {
          "en": "0.1-0.3 mg/day (individualized)",
          "ar": "0.1-0.3 مجم/يوم (حسب الحالة)"
        },
        "usage": {
          "en": "Subcutaneous injection; requires careful titration",
          "ar": "حقن تحت الجلد؛ يتطلب تعديل دقيق للجرعة"
        },
        "notFor": {
          "en": "Anti-aging or performance enhancement in healthy individuals",
          "ar": "مكافحة الشيخوخة أو تحسين الأداء لدى الأفراد الأصحاء"
        },
        "warnings": {
          "en": "Expensive. Side effects: joint pain, insulin resistance, carpal tunnel, increased cancer risk. Illegal for athletic enhancement.",
          "ar": "باهظ الثمن. الآثار الجانبية: آلام المفاصل، مقاومة الأنسولين، متلازمة النفق الرسغي، زيادة خطر الإصابة بالسرطان. غير قانوني لتحسين الأداء الرياضي."
        }
      },
      {
        "name": {
          "en": "SARMs (e.g., Ostarine, Ligandrol)",
          "ar": "SARMs (مثل أوستارين، ليغاندرول)"
        },
        "for": {
          "en": "Not FDA-approved; occasionally used off-label for muscle wasting in research settings",
          "ar": "غير معتمد من إدارة الأغذية والأدوية؛ يستخدم أحيانًا خارج النطاق لهزال العضلات في إعدادات البحث"
        },
        "dose": {
          "en": "Varies by compound (e.g., Ostarine 10-30mg/day)",
          "ar": "تختلف حسب المركب (مثال: أوستارين 10-30 مجم/يوم)"
        },
        "usage": {
          "en": "Oral; cycles typically 8-12 weeks",
          "ar": "عن طريق الفم؛ الدورات عادة 8-12 أسبوعًا"
        },
        "notFor": {
          "en": "General fitness or athletic performance",
          "ar": "اللياقة العامة أو الأداء الرياضي"
        },
        "warnings": {
          "en": "Not approved for human use. Risks: liver toxicity, hormonal suppression, cardiovascular effects. Banned by WADA.",
          "ar": "غير معتمد للاستخدام البشري. المخاطر: سمية الكبد، كبت الهرمونات، آثار القلب والأوعية الدموية. محظور من قبل الوكالة العالمية لمكافحة المنشطات."
        }
      },
      {
        "name": {
          "en": "Clenbuterol",
          "ar": "كلينبوتيرول"
        },
        "for": {
          "en": "Asthma treatment (veterinary use common); not approved for weight loss",
          "ar": "علاج الربو (الاستخدام البيطري شائع)؛ غير معتمد لفقدان الوزن"
        },
        "dose": {
          "en": "20-60 mcg/day (escalating dose)",
          "ar": "20-60 ميكروغرام/يوم (جرعة متزايدة)"
        },
        "usage": {
          "en": "Oral; cycles typically 2 weeks on/2 weeks off",
          "ar": "عن طريق الفم؛ الدورات عادة 2 أسبوعًا تناول/2 أسبوعًا راحة"
        },
        "notFor": {
          "en": "Weight loss or performance enhancement",
          "ar": "فقدان الوزن أو تحسين الأداء"
        },
        "warnings": {
          "en": "Not approved for human use in many countries. Side effects: tachycardia, tremors, hypokalemia, cardiac hypertrophy. Banned in sports.",
          "ar": "غير معتمد للاستخدام البشري في العديد من البلدان. الآثار الجانبية: تسرع القلب، الرعشة، نقص بوتاسيوم الدم، تضخم عضلة القلب. محظور في الرياضة."
        }
      },
      {
        "name": {
          "en": "Aromatase Inhibitors (e.g., Anastrozole)",
          "ar": "مثبطات الأروماتاز (مثل أناستروزول)"
        },
        "for": {
          "en": "Estrogen-sensitive breast cancer; off-label for TRT side effect management",
          "ar": "سرطان الثدي الحساس للإستروجين؛ خارج النطاق لإدارة الآثار الجانبية لـ TRT"
        },
        "dose": {
          "en": "0.5-1 mg/week (for TRT side effects)",
          "ar": "0.5-1 مجم/أسبوع (للآثار الجانبية لـ TRT)"
        },
        "usage": {
          "en": "Oral; requires estrogen level monitoring",
          "ar": "عن طريق الفم؛ يتطلب مراقبة مستويات الإستروجين"
        },
        "notFor": {
          "en": "Estrogen suppression in healthy individuals",
          "ar": "كبت الإستروجين لدى الأفراد الأصحاء"
        },
        "warnings": {
          "en": "Can cause joint pain, bone loss, negative lipid profiles. Should only be used with documented high estradiol.",
          "ar": "يمكن أن يسبب آلام المفاصل، فقدان العظام، ملامح الدهون السلبية. يجب استخدامه فقط مع وجود مستويات عالية من الإستراديول موثقة."
        }
      },
      {
        "name": {
          "en": "DHEA (Dehydroepiandrosterone)",
          "ar": "DHEA (ديهيدرو إبياندروستيرون)"
        },
        "for": {
          "en": "Adrenal insufficiency; sometimes for age-related hormone decline",
          "ar": "قصور الغدة الكظرية؛ أحيانًا لانخفاض الهرمونات المرتبط بالعمر"
        },
        "dose": {
          "en": "25-50 mg/day",
          "ar": "25-50 مجم/يوم"
        },
        "usage": {
          "en": "Oral; morning administration preferred",
          "ar": "عن طريق الفم؛ يفضل الإعطاء في الصباح"
        },
        "notFor": {
          "en": "General anti-aging or performance enhancement",
          "ar": "مكافحة الشيخوخة العامة أو تحسين الأداء"
        },
        "warnings": {
          "en": "May increase estrogen/DHT; can cause acne, hair loss, mood changes. Banned by most sports organizations.",
          "ar": "قد يزيد الإستروجين/DHT؛ يمكن أن يسبب حب الشباب، تساقط الشعر، تغيرات المزاج. محظور من قبل معظم المنظمات الرياضية."
        }
      },
      {
        "name": {
          "en": "Erythropoietin (EPO)",
          "ar": "إريثروبويتين (EPO)"
        },
        "for": {
          "en": "Anemia due to chronic kidney disease or chemotherapy",
          "ar": "فقر الدم بسبب أمراض الكلى المزمنة أو العلاج الكيميائي"
        },
        "dose": {
          "en": "50-100 IU/kg 3x/week (individualized)",
          "ar": "50-100 وحدة دولية/كجم 3 مرات/أسبوع (حسب الحالة)"
        },
        "usage": {
          "en": "Subcutaneous or IV injection; requires hemoglobin monitoring",
          "ar": "حقن تحت الجلد أو الوريد؛ يتطلب مراقبة الهيموجلوبين"
        },
        "notFor": {
          "en": "Endurance enhancement in healthy athletes",
          "ar": "تحسين التحمل لدى الرياضيين الأصحاء"
        },
        "warnings": {
          "en": "Increases thrombosis risk; can cause hypertension, seizures. Banned in sports; dangerous without medical supervision.",
          "ar": "يزيد خطر الجلطات؛ يمكن أن يسبب ارتفاع ضغط الدم، النوبات. محظور في الرياضة؛ خطير بدون إشراف طبي."
        }
      }
    ],
    "medicalSupervisionRequirements": [
      {
        "en": "Comprehensive Diagnosis (bloodwork, medical history, physical exam)",
        "ar": "تشخيص شامل (فحوصات دم، التاريخ الطبي، الفحص البدني)"
      },
      {
        "en": "Risk-Benefit Assessment",
        "ar": "تقييم المخاطر والفوائد"
      },
      {
        "en": "Individualized Dosing & Monitoring",
        "ar": "الجرعات الشخصية والمراقبة"
      },
      {
        "en": "Lifestyle Foundation",
        "ar": "أساسيات نمط الحياة"
      },
      {
        "en": "Legal & Ethical Prescribing",
        "ar": "الوصفة الطبية القانونية والأخلاقية"
      },
      {
        "en": "Regular Follow-up and Lab Monitoring",
        "ar": "المتابعة المنتظمة ومراقبة المختبر"
      },
      {
        "en": "Management of Side Effects",
        "ar": "إدارة الآثار الجانبية"
      }
    ]
  },
  "ScenarioSpecificApproach": [
    {
      "scenario": {
        "en": "Slow Muscle Building",
        "ar": "بناء عضلي بطيء"
      },
      "keyNutritionalFocus": {
        "en": "High Protein (1.6-2.2g/kg), Caloric Surplus, Creatine",
        "ar": "بروتين عالٍ (1.6-2.2جم/كجم)، فائض حراري، كرياتين"
      },
      "keyExerciseFocus": {
        "en": "Progressive Overload, Sufficient Volume/Frequency",
        "ar": "الحمل الزائد التدريجي، حجم/تكرار كافٍ"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out hypogonadism (Testosterone levels); consider GH deficiency if severe",
        "ar": "استبعاد قصور الغدد التناسلية (مستويات التستوستيرون)؛ النظر في نقص هرمون النمو إذا كان شديدًا"
      }
    },
    {
      "scenario": {
        "en": "Slow Fat Burning",
        "ar": "حرق دهون بطيء"
      },
      "keyNutritionalFocus": {
        "en": "Caloric Deficit, High Protein, High Fiber, NEAT",
        "ar": "عجز حراري، بروتين عالٍ، ألياف عالية، نشاط غير تمريني (NEAT)"
      },
      "keyExerciseFocus": {
        "en": "Resistance Training + HIIT + MISS, Increase Daily Activity",
        "ar": "التدريب المقاوم + HIIT + MISS، زيادة النشاط اليومي"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out hypothyroidism, insulin resistance; consider Metformin if IR confirmed",
        "ar": "استبعاد قصور الغدة الدرقية، مقاومة الأنسولين؛ النظر في ميتفورمين إذا تم تأكيد مقاومة الأنسولين"
      }
    },
    {
      "scenario": {
        "en": "Stubborn Fat",
        "ar": "الدهون العنيدة"
      },
      "keyNutritionalFocus": {
        "en": "Sustained Deficit, High Protein, Manage Stress/Sleep",
        "ar": "عجز مستدام، بروتين عالٍ، إدارة التوتر/النوم"
      },
      "keyExerciseFocus": {
        "en": "Consistent Deficit + Resistance Training + HIIT",
        "ar": "عجز ثابت + تدريب مقاوم + HIIT"
      },
      "potentialMedicalConsiderations": {
        "en": "Address underlying insulin resistance; consider thyroid optimization if subclinical",
        "ar": "معالجة مقاومة الأنسولين الكامنة؛ النظر في تحسين الغدة الدرقية إذا كانت دون السريرية"
      }
    },
    {
      "scenario": {
        "en": "Stagnant Muscle Mass",
        "ar": "ركود الكتلة العضلية"
      },
      "keyNutritionalFocus": {
        "en": "Ensure Adequate Calories/Protein, Nutrient Timing",
        "ar": "ضمان سعرات حرارية/بروتين كافية، توقيت المغذيات"
      },
      "keyExerciseFocus": {
        "en": "Re-evaluate Program: Form, Volume, Intensity, Recovery",
        "ar": "إعادة تقييم البرنامج: الشكل، الحجم، الشدة، التعافي"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out hormonal imbalances (testosterone, thyroid, cortisol); consider myostatin testing in research settings",
        "ar": "استبعاد الاختلالات الهرمونية (التستوستيرون، الغدة الدرقية، الكورتيزول)؛ النظر في اختبار الميوستاتين في إعدادات البحث"
      }
    },
    {
      "scenario": {
        "en": "Beginner Weight Plateau",
        "ar": "هضبة وزن المبتدئين"
      },
      "keyNutritionalFocus": {
        "en": "Master Form, Increase Reps then Weight, Protein",
        "ar": "إتقان الشكل، زيادة التكرارات ثم الوزن، البروتين"
      },
      "keyExerciseFocus": {
        "en": "Focus on Technique & Progressive Reps, Consistency",
        "ar": "التركيز على التقنية والتكرارات التدريجية، الاستمرارية"
      },
      "potentialMedicalConsiderations": {
        "en": "Rarely needed; focus on fundamentals; rule out underlying medical conditions if persistent",
        "ar": "نادرًا ما يحتاج؛ التركيز على الأساسيات؛ استبعاد الحالات الطبية الكامنة إذا كانت مستمرة"
      }
    },
    {
      "scenario": {
        "en": "Advanced Weight Plateau",
        "ar": "هضبة وزن المتقدمين"
      },
      "keyNutritionalFocus": {
        "en": "Optimize Nutrition Timing/Recovery, Creatine, Beta-Alanine",
        "ar": "تحسين توقيت التغذية/التعافي، الكرياتين، بيتا-ألانين"
      },
      "keyExerciseFocus": {
        "en": "Periodization, Advanced Overload Techniques, Deloads",
        "ar": "التدوير الدوري، تقنيات الحمل الزائد المتقدمة، التخفيف"
      },
      "potentialMedicalConsiderations": {
        "en": "Rule out overtraining syndrome, hormonal issues; consider advanced diagnostics in clinical settings",
        "ar": "استبعاد متلازمة الإفراط في التدريب، المشاكل الهرمونية؛ النظر في التشخيصات المتقدمة في الإعدادات السريرية"
      }
    }
  ],
  "References": [
    "Morton, R. W., et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine, 52(6), 376–384. https://bjsm.bmj.com/content/52/6/376",
    "Kreider, R. B., et al. (2017). International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition, 14(1), 18. https://jissn.biomedcentral.com/articles/10.1186/s12970-017-0173-z",
    "Saunders, B., et al. (2012). Beta-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis. Amino Acids, 43(1), 25–37. https://link.springer.com/article/10.1007/s00726-011-1200-z",
    "Southward, K., et al. (2022). The effect of caffeine on exercise performance: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 19(1), 63. https://jissn.biomedcentral.com/articles/10.1186/s12970-022-00832-8",
    "Schoenfeld, B. J., et al. (2017). Resistance Training Recommendations to Maximize Muscle Hypertrophy: An Evidence-Based Approach. Strength and Conditioning Journal, 39(5), 34–47. https://journals.lww.com/nsca-scj/fulltext/2017/10000/resistance_training_recommendations_to_maximize.5.aspx",
    "Clark, J. E. (2018). Diet, exercise or diet with exercise: comparing the effectiveness of treatment options for weight-loss and weight-loss maintenance. Journal of Human Nutrition and Dietetics, 31(3), 329–339. https://onlinelibrary.wiley.com/doi/full/10.1111/jhn.12532",
    "Bhasin, S., et al. (2018). Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://academic.oup.com/jcem/article/103/5/1715/4929253",
    "Garber, J. R., et al. (2012). Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22(12), 1200–1235. https://www.liebertpub.com/doi/10.1089/thy.2012.0205",
    "Fullagar, H. H. K., et al. (2015). The role of sleep in athletic performance. Frontiers in Physiology, 6, 142. https://www.frontiersin.org/articles/10.3389/fphys.2015.00142/full",
    "Hoffman, J. R., et al. (2009). Position stand on androgen and human growth hormone use. Journal of the International Society of Sports Nutrition, 6(Suppl 1), S7. https://jissn.biomedcentral.com/articles/10.1186/1550-2783-6-S1-S7",
    "World Anti-Doping Agency. (2023). 2023 Prohibited List. https://www.wada-ama.org/en/content/2023-prohibited-list"
  ]
}
managemnt of obesity by drugs
{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Orlistat",
        "brand": ["Xenical", "Alli"],
        "generic_names_by_country": {
          "Egypt": "أورليستات",
          "KSA": "أورليستات",
          "UAE": "أورليستات",
          "USA": "Orlistat",
          "UK": "Orlistat",
          "India": "Orlistat",
          "Australia": "Orlistat"
        }
      },
      "doses": {
        "typical_dose": "120 mg three times daily",
        "starting_dose": "60 mg (OTC) or 120 mg (prescription)",
        "maintenance_dose": "120 mg three times daily",
        "maximum_dose": "120 mg three times daily"
      },
      "dosage_regimen": "Taken with each fat-containing meal or up to 1 hour after the meal. Skip if meal is missed or contains no fat.",
      "method_of_administration": "Oral (capsule)",
      "mechanism_of_action": "Inhibits pancreatic and gastric lipases, preventing absorption of ~30% of dietary fats. Works locally in the GI tract with minimal systemic absorption.",
      "side_effects": {
        "common": ["Oily spotting", "Flatus with discharge", "Fecal urgency", "Oily stools", "Increased defecation", "Abdominal pain"],
        "serious": ["Severe liver injury", "Kidney stones", "Vitamin deficiency (A, D, E, K)", "Oxalate nephropathy"]
      },
      "how_to_avoid_side_effects": [
        "Take multivitamin 2 hours before/after dose",
        "Follow low-fat diet (<30% calories from fat)",
        "Increase fluid intake",
        "Avoid high-fat meals",
        "Monitor liver function periodically"
      ],
      "interactions": [
        "Warfarin (reduced absorption)",
        "Cyclosporine (avoid concurrent use)",
        "Levothyroxine (take 4 hours apart)",
        "Antiepileptics (reduced efficacy)",
        "Amiodarone (reduced absorption)"
      ],
      "contraindications": [
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Pregnancy",
        "Allergy to orlistat",
        "Anorexia nervosa"
      ],
      "global_availability": "Available in most countries. OTC in USA (Alli), prescription-only in many others.",
      "cost_considerations": "Generic versions available. Cost varies by region: ~$50-100/month in USA, ~£20-30/month in UK.",
      "recent_updates": "2021 study showed 5.8% greater weight loss vs placebo at 1 year (JAMA).",
      "references": [
        {
          "title": "Systematic Review of Orlistat",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909198/"
        },
        {
          "title": "FDA Label for Xenical",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021662s034lbl.pdf"
        },
        {
          "title": "Orlistat Efficacy Update",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2779103"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine-Topiramate",
        "brand": ["Qsymia"],
        "generic_names_by_country": {
          "Egypt": "فينترمين-توبرامات",
          "KSA": "فينترمين-توبرامات",
          "UAE": "فينترمين-توبرامات",
          "USA": "Phentermine-Topiramate",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "starting_dose": "3.75 mg/23 mg daily",
        "maintenance_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "maximum_dose": "15 mg/92 mg daily"
      },
      "dosage_regimen": "Once daily in the morning with or without food. Dose escalation every 2 weeks.",
      "method_of_administration": "Oral (extended-release capsule)",
      "mechanism_of_action": "Phentermine: Norepinephrine-releasing agent (appetite suppression). Topiramate: GABA agonist/glutamate antagonist (satiety enhancement). Synergistic effect on weight loss.",
      "side_effects": {
        "common": ["Dry mouth", "Constipation", "Paresthesia", "Insomnia", "Dizziness", "Taste perversion"],
        "serious": ["Tachycardia", "Suicidal ideation", "Cognitive impairment", "Teratogenicity (cleft lip/palate)", "Metabolic acidosis"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Monitor heart rate regularly",
        "Use effective contraception",
        "Gradual dose escalation",
        "Avoid alcohol",
        "Monitor mood changes"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Oral contraceptives (reduced efficacy)",
        "CNS depressants (additive effects)",
        "Carbonic anhydrase inhibitors (increased stone risk)",
        "Antihypertensives (reduced efficacy)"
      ],
      "contraindications": [
        "Glaucoma",
        "Hyperthyroidism",
        "Pregnancy",
        "Recent MAOI use",
        "History of heart attack/stroke",
        "Bipolar disorder"
      ],
      "global_availability": "Approved in USA (2012), not approved in EU/UK/Australia due to safety concerns. Available in Gulf countries.",
      "cost_considerations": "High cost: ~$200-300/month in USA. Not covered by many insurance plans.",
      "recent_updates": "2023 study showed 10.9% weight loss at 1 year vs 1.6% with placebo (Obesity Week).",
      "references": [
        {
          "title": "Qsymia Efficacy and Safety Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366128/"
        },
        {
          "title": "Endocrine Society Guidelines",
          "link": "https://journal.endocrine.org/doi/full/10.1210/jc.2015-3183"
        },
        {
          "title": "Long-term Qsymia Outcomes",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/obr.13527"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Liraglutide",
        "brand": ["Saxenda"],
        "generic_names_by_country": {
          "Egypt": "ليراجلوتايد",
          "KSA": "ليراجلوتايد",
          "UAE": "ليراجلوتايد",
          "USA": "Liraglutide",
          "UK": "Liraglutide",
          "India": "Liraglutide",
          "Australia": "Liraglutide"
        }
      },
      "doses": {
        "typical_dose": "3.0 mg daily",
        "starting_dose": "0.6 mg daily",
        "maintenance_dose": "3.0 mg daily",
        "maximum_dose": "3.0 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Increase by 0.6 mg weekly until 3.0 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, promotes satiety. Activates GLP-1 receptors in hypothalamus.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Headache", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors", "Hypoglycemia (with insulin)"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose and escalate slowly",
        "Eat smaller meals",
        "Stay hydrated",
        "Monitor for abdominal pain",
        "Avoid in patients with pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (increased hypoglycemia risk)",
        "ACE inhibitors (worsened renal function)",
        "Sulfonylureas (increased hypoglycemia)"
      ],
      "contraindications": [
        "Personal/family history of medullary thyroid carcinoma",
        "Multiple Endocrine Neoplasia type 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2014), EU (2015), UK, Australia, Gulf countries. Widely available globally.",
      "cost_considerations": "Very high cost: ~$1,300/month in USA, ~£300/month in UK. Often requires prior authorization.",
      "recent_updates": "2022 meta-analysis showed 5.4 kg greater weight loss vs placebo (Lancet Diabetes Endocrinol).",
      "references": [
        {
          "title": "SCALE Obesity and Prediabetes Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892"
        },
        {
          "title": "GLP-1 RAs for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30415-9/fulltext"
        },
        {
          "title": "Liraglutide Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1607141"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Semaglutide",
        "brand": ["Wegovy", "Ozempic"],
        "generic_names_by_country": {
          "Egypt": "سيماجلوتايد",
          "KSA": "سيماجلوتايد",
          "UAE": "سيماجلوتايد",
          "USA": "Semaglutide",
          "UK": "Semaglutide",
          "India": "Semaglutide",
          "Australia": "Semaglutide"
        }
      },
      "doses": {
        "typical_dose": "2.4 mg weekly",
        "starting_dose": "0.25 mg weekly",
        "maintenance_dose": "2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks until 2.4 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide but with longer half-life (7 days) and higher potency. Reduces appetite via central nervous system effects.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Abdominal pain", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Diabetic retinopathy", "Acute kidney injury", "Gallbladder cancer risk"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat foods",
        "Monitor blood sugar in diabetics",
        "Discontinue if pancreatitis suspected",
        "Hydration",
        "Monitor retinopathy in diabetics"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Oral contraceptives (reduced efficacy)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe renal impairment",
        "Diabetic retinopathy"
      ],
      "global_availability": "Approved in USA (2021), EU (2022), UK, Australia, Gulf countries. Shortages reported globally due to high demand.",
      "cost_considerations": "Extremely high cost: ~$1,600/month in USA, ~£200/month in UK. Limited insurance coverage.",
      "recent_updates": "2023 SELECT trial showed 20% weight loss with cardiovascular benefits (NEJM).",
      "references": [
        {
          "title": "STEP Trials Program",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
        },
        {
          "title": "Semaglutide for Obesity: Systematic Review",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
        },
        {
          "title": "SELECT Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Bupropion-Naltrexone",
        "brand": ["Contrave"],
        "generic_names_by_country": {
          "Egypt": "بوبروبيون-نالتريكسون",
          "KSA": "بوبروبيون-نالتريكسون",
          "UAE": "بوبروبيون-نالتريكسون",
          "USA": "Bupropion-Naltrexone",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "32 mg/360 mg twice daily",
        "starting_dose": "8 mg/90 mg daily",
        "maintenance_dose": "32 mg/360 mg twice daily",
        "maximum_dose": "32 mg/360 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Increase gradually over 4 weeks to target dose.",
      "method_of_administration": "Oral (extended-release tablet)",
      "mechanism_of_action": "Bupropion: Dopamine/norepinephrine reuptake inhibitor. Naltrexone: Opioid antagonist. Combined effect on hypothalamic POMC neurons to reduce appetite.",
      "side_effects": {
        "common": ["Nausea", "Headache", "Constipation", "Dizziness", "Insomnia", "Dry mouth"],
        "serious": ["Seizures", "Hypertension", "Hepatotoxicity", "Suicidal ideation", "Angle-closure glaucoma"]
      },
      "how_to_avoid_side_effects": [
        "Avoid high-fat meals",
        "Monitor blood pressure",
        "Do not exceed dose",
        "Avoid alcohol",
        "Use in patients without seizure history",
        "Monitor liver function"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Opioid analgesics (reduced efficacy)",
        "Antidepressants (increased seizure risk)",
        "CYP2B6 inhibitors (increased bupropion levels)",
        "Dopamine antagonists (reduced efficacy)"
      ],
      "contraindications": [
        "Uncontrolled hypertension",
        "Seizure disorder",
        "Opioid dependence",
        "Pregnancy",
        "Liver failure",
        "Eating disorders"
      ],
      "global_availability": "Approved in USA (2014), not approved in EU/UK/Australia. Available in Gulf countries with restrictions.",
      "cost_considerations": "High cost: ~$200-300/month in USA. Limited insurance coverage.",
      "recent_updates": "2023 study showed 5.7% greater weight loss vs placebo at 1 year (Obesity).",
      "references": [
        {
          "title": "Contrave Clinical Trials",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669984/"
        },
        {
          "title": "Obesity Pharmacotherapy Review",
          "link": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.056739"
        },
        {
          "title": "Bupropion-Naltrexone Long-term Safety",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14523"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Setmelanotide",
        "brand": ["Imcivree"],
        "generic_names_by_country": {
          "Egypt": "سيتميلانوتايد",
          "KSA": "سيتميلانوتايد",
          "UAE": "سيتميلانوتايد",
          "USA": "Setmelanotide",
          "UK": "Setmelanotide",
          "India": "Not available",
          "Australia": "Not available"
        }
      },
      "doses": {
        "typical_dose": "1-3 mg daily",
        "starting_dose": "1 mg daily",
        "maintenance_dose": "1-3 mg daily",
        "maximum_dose": "3 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Individualize dose based on response.",
      "method_of_administration": "Subcutaneous (vial and syringe)",
      "mechanism_of_action": "MC4R agonist: Restores impaired melanocortin signaling in genetic obesity syndromes (POMC, PCSK1, LEPR deficiencies). Activates POMC neurons in hypothalamus.",
      "side_effects": {
        "common": ["Injection site reactions", "Nausea", "Headache", "Diarrhea", "Back pain", "Fatigue"],
        "serious": ["Skin hyperpigmentation", "Spontaneous penile erections", "Depression", "Suicidal ideation"]
      },
      "how_to_avoid_side_effects": [
        "Rotate injection sites",
        "Monitor mood changes",
        "Avoid sun exposure",
        "Use in confirmed genetic obesity only",
        "Monitor for sexual dysfunction",
        "Psychiatric monitoring"
      ],
      "interactions": [
        "Limited data: Potential interactions with CYP450 substrates",
        "Avoid concurrent weight loss medications",
        "Melanocortin agonists (additive effects)"
      ],
      "contraindications": [
        "Non-genetic obesity",
        "Pregnancy",
        "Severe renal impairment",
        "History of depression",
        "Skin cancer history"
      ],
      "global_availability": "Approved in USA (2020), EU (2021), UK. Not available in most developing countries. Requires genetic testing.",
      "cost_considerations": "Extremely high cost: ~$10,000/month in USA. Often covered by insurance for genetic indications only.",
      "recent_updates": "2023 study showed 25% weight loss in POMC deficiency (Nature Medicine).",
      "references": [
        {
          "title": "Setmelanotide for Genetic Obesity",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1907332"
        },
        {
          "title": "FDA Label for Imcivree",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf"
        },
        {
          "title": "Setmelanotide Long-term Outcomes",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00123-4/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Tirzepatide",
        "brand": ["Mounjaro", "Zepbound"],
        "generic_names_by_country": {
          "Egypt": "تيرزيباتايد",
          "KSA": "تيرزيباتايد",
          "UAE": "تيرزيباتايد",
          "USA": "Tirzepatide",
          "UK": "Tirzepatide",
          "India": "Tirzepatide",
          "Australia": "Tirzepatide"
        }
      },
      "doses": {
        "typical_dose": "5-15 mg weekly",
        "starting_dose": "2.5 mg weekly",
        "maintenance_dose": "5-15 mg weekly",
        "maximum_dose": "15 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase by 2.5 mg every 4 weeks until target dose.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "Dual GIP and GLP-1 receptor agonist: Enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through dual incretin pathways. GIP component enhances adipocyte lipid metabolism.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Decreased appetite", "Abdominal pain"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Diabetic retinopathy", "Hypoglycemia"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Eat smaller, low-fat meals",
        "Stay hydrated",
        "Monitor blood glucose in diabetics",
        "Avoid dehydration",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2022), EU (2023), UK, Australia, Gulf countries. Shortages reported globally.",
      "cost_considerations": "Extremely high cost: ~$1,100/month in USA, ~£300/month in UK. Limited insurance coverage for obesity indication.",
      "recent_updates": "2023 SURMOUNT trials showed 22.5% weight loss at 72 weeks (NEJM).",
      "references": [
        {
          "title": "SURMOUNT-1 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038"
        },
        {
          "title": "Tirzepatide for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00473-3/fulltext"
        },
        {
          "title": "SURMOUNT-4 Long-term Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Metformin",
        "brand": ["Glucophage", "Fortamet"],
        "generic_names_by_country": {
          "Egypt": "ميتفورمين",
          "KSA": "ميتفورمين",
          "UAE": "ميتفورمين",
          "USA": "Metformin",
          "UK": "Metformin",
          "India": "Metformin",
          "Australia": "Metformin"
        }
      },
      "doses": {
        "typical_dose": "500-2000 mg daily",
        "starting_dose": "500 mg once or twice daily",
        "maintenance_dose": "1000-2000 mg daily",
        "maximum_dose": "2550 mg daily"
      },
      "dosage_regimen": "Twice daily with meals. Increase dose gradually to minimize GI side effects.",
      "method_of_administration": "Oral (tablet/extended-release)",
      "mechanism_of_action": "Decreases hepatic glucose production, increases insulin sensitivity, and may reduce appetite through AMPK activation. Modulates gut microbiota.",
      "side_effects": {
        "common": ["Diarrhea", "Nausea", "Abdominal discomfort", "Metallic taste", "Vitamin B12 deficiency"],
        "serious": ["Lactic acidosis", "Hypoglycemia (with other agents)", "Hepatotoxicity"]
      },
      "how_to_avoid_side_effects": [
        "Take with meals",
        "Start with low dose and titrate slowly",
        "Use extended-release formulation",
        "Monitor B12 levels long-term",
        "Avoid in renal impairment",
        "Discontinue before procedures with contrast"
      ],
      "interactions": [
        "Iodinated contrast media (discontinue before procedures)",
        "Alcohol (increased lactic acidosis risk)",
        "Cimetidine (increased metformin levels)",
        "Furosemide (reduced efficacy)",
        "NSAIDs (increased renal risk)"
      ],
      "contraindications": [
        "Severe renal impairment (eGFR <30 mL/min)",
        "Acute or chronic metabolic acidosis",
        "Hypersensitivity to metformin",
        "Acute liver disease",
        "Heart failure"
      ],
      "global_availability": "Available worldwide. First-line therapy for type 2 diabetes. Used off-label for obesity.",
      "cost_considerations": "Very low cost: ~$4-20/month for generic versions. Widely covered by insurance.",
      "recent_updates": "2023 meta-analysis showed 2.5 kg greater weight loss vs placebo (Diabetes Care).",
      "references": [
        {
          "title": "Metformin for Obesity: Systematic Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239984/"
        },
        {
          "title": "ADA Standards of Care",
          "link": "https://diabetesjournals.org/care/article/46/Supplement_1/S140/148899/Standards-of-Medical-Care-in-Diabetes2023"
        },
        {
          "title": "Metformin Mechanisms Update",
          "link": "https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00152-2"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine",
        "brand": ["Adipex-P", "Lomaira"],
        "generic_names_by_country": {
          "Egypt": "فينترمين",
          "KSA": "فينترمين",
          "UAE": "فينترمين",
          "USA": "Phentermine",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "15-37.5 mg daily",
        "starting_dose": "8 mg (Lomaira) or 15 mg (Adipex-P)",
        "maintenance_dose": "15-37.5 mg daily",
        "maximum_dose": "37.5 mg daily"
      },
      "dosage_regimen": "Once daily in the morning or three times daily before meals (Lomaira). Short-term use only (≤12 weeks).",
      "method_of_administration": "Oral (tablet/capsule)",
      "mechanism_of_action": "Sympathomimetic amine: Stimulates norepinephrine release, suppressing appetite through hypothalamic action. Increases energy expenditure.",
      "side_effects": {
        "common": ["Dry mouth", "Insomnia", "Headache", "Tachycardia", "Constipation", "Hypertension"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence", "Stroke"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease",
        "Do not exceed recommended dose",
        "Avoid abrupt discontinuation"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Insulin/oral hypoglycemics (hypoglycemia risk)",
        "Sympathomimetics (additive effects)",
        "SSRIs (increased serotonin risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy",
        "Agitated states"
      ],
      "global_availability": "Approved in USA (1959), Gulf countries. Not approved in EU/UK/Australia due to safety concerns. Controlled substance in USA.",
      "cost_considerations": "Low cost: ~$20-50/month for generic versions. Often not covered by insurance.",
      "recent_updates": "2023 study showed 3.6% greater weight loss vs placebo at 12 weeks (Obesity Science & Practice).",
      "references": [
        {
          "title": "Phentermine for Weight Loss: Meta-Analysis",
          "link": "https://journals.lww.com/co-endocrinology/Fulltext/2015/02000/Pharmacotherapy_for_obesity.7.aspx"
        },
        {
          "title": "FDA Label for Adipex-P",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021876s031lbl.pdf"
        },
        {
          "title": "Phentermine Cardiovascular Safety",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1606172"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Dulaglutide",
        "brand": ["Trulicity"],
        "generic_names_by_country": {
          "Egypt": "دولاجلوتايد",
          "KSA": "دولاجلوتايد",
          "UAE": "دولاجلوتايد",
          "USA": "Dulaglutide",
          "UK": "Dulaglutide",
          "India": "Dulaglutide",
          "Australia": "Dulaglutide"
        }
      },
      "doses": {
        "typical_dose": "1.5-4.5 mg weekly",
        "starting_dose": "0.75 mg weekly",
        "maintenance_dose": "1.5-4.5 mg weekly",
        "maximum_dose": "4.5 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide/semaglutide but with once-weekly dosing. Enhances glucose-dependent insulin secretion and suppresses glucagon.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Abdominal pain", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors", "Hypoglycemia"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat meals",
        "Monitor for abdominal pain",
        "Stay hydrated",
        "Avoid in pancreatitis history",
        "Monitor renal function"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Sulfonylureas (increased hypoglycemia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2014), EU, UK, Australia, Gulf countries. Widely available globally.",
      "cost_considerations": "High cost: ~$800/month in USA, ~£70/month in UK. Often covered for diabetes but not obesity.",
      "recent_updates": "2023 AWARD-11 trial showed 6.2% weight loss with 4.5 mg dose (Lancet).",
      "references": [
        {
          "title": "AWARD-11 Trial",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02374-1/fulltext"
        },
        {
          "title": "GLP-1 RAs for Weight Management",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        },
        {
          "title": "Dulaglutide Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1603827"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Lorcaserin",
        "brand": ["Belviq"],
        "generic_names_by_country": {
          "Egypt": "لوركاسيرين",
          "KSA": "لوركاسيرين",
          "UAE": "لوركاسيرين",
          "USA": "Withdrawn",
          "UK": "Never approved",
          "India": "Never approved",
          "Australia": "Never approved"
        }
      },
      "doses": {
        "typical_dose": "10 mg twice daily",
        "starting_dose": "10 mg twice daily",
        "maintenance_dose": "10 mg twice daily",
        "maximum_dose": "10 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Discontinue if <5% weight loss after 12 weeks.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Selective serotonin 2C receptor agonist: Promotes satiety through hypothalamic pro-opiomelanocortin (POMC) neurons. Reduces food intake.",
      "side_effects": {
        "common": ["Headache", "Dizziness", "Fatigue", "Nausea", "Dry mouth", "Constipation"],
        "serious": ["Valvular heart disease", "Serotonin syndrome", "Cognitive impairment", "Cancer risk", "Psychiatric disorders"]
      },
      "how_to_avoid_side_effects": [
        "Regular cardiac monitoring",
        "Avoid concurrent serotonergic drugs",
        "Monitor for mood changes",
        "Limit duration of use",
        "Avoid in patients with heart failure",
        "Avoid abrupt discontinuation"
      ],
      "interactions": [
        "SSRIs/SNRIs (serotonin syndrome risk)",
        "MAO inhibitors (hypertensive crisis)",
        "Triptans (serotonin syndrome)",
        "Dextromethorphan (serotonin syndrome)",
        "St. John's Wort (serotonin syndrome)"
      ],
      "contraindications": [
        "Pregnancy",
        "Severe renal impairment",
        "History of valvular heart disease",
        "Concurrent use of serotonergic drugs",
        "Pulmonary hypertension"
      ],
      "withdrawal_note": "Withdrawn from US market in February 2020 due to increased cancer incidence in clinical trials. Never approved in EU/UK/Australia.",
      "global_availability": "Withdrawn globally. Not available in any market.",
      "cost_considerations": "Not applicable (withdrawn).",
      "recent_updates": "2021 FDA analysis confirmed 1.3x increased cancer risk (NEJM).",
      "references": [
        {
          "title": "FDA Drug Safety Communication",
          "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-against-use-lorcaserin-belviq-belviq-xr"
        },
        {
          "title": "Lorcaserin Safety Review",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2006201"
        },
        {
          "title": "Lorcaserin Cancer Risk Analysis",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2008731"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences. Genetic testing required for setmelanotide.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs. Tirzepatide monotherapy preferred over combinations.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, liver function, mental health, and nutritional status. Echocardiogram for serotonergic agents.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet (500-750 kcal deficit) and increased physical activity (150+ min/week). Behavioral support essential.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months (discontinue if <5% weight loss). GLP-1 RAs may be used indefinitely.",
    "special_populations": {
      "elderly": "Caution with CNS-acting drugs. Lower starting doses recommended.",
      "renal_impairment": "Avoid or adjust dose for most agents. GLP-1 RAs require dose adjustment.",
      "hepatic_impairment": "Avoid orlistat, phentermine, bupropion-naltrexone. Others require caution.",
      "cardiovascular_disease": "Avoid phentermine, lorcaserin. GLP-1 RAs preferred in established CVD.",
      "pregnancy": "All weight loss medications contraindicated. Discontinue 2 months before conception.",
      "pediatrics": "Limited options: orlistat (≥12 years), liraglutide (≥12 years), phentermine (≥16 years)."
    },
    "cost_effectiveness": "Orlistat and metformin most cost-effective. GLP-1 RAs and tirzepatide have high upfront costs but may reduce long-term complications. Insurance coverage varies widely.",
    "future_directions": "Oral GLP-1 RAs (orforglipron), amylin analogues (cagrilintide), and dual/triple agonists in development. Focus on cardiovascular and renal benefits beyond weight loss."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      },
      {
        "title": "ADA Obesity Management Guidelines",
        "link": "https://care.diabetesjournals.org/content/39/Supplement_1/S88"
      },
      {
        "title": "NICE Guidelines [NG189]",
        "link": "https://www.nice.org.uk/guidance/ng189"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      },
      {
        "title": "Comparative Effectiveness of Weight Loss Medications",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
      }
    ],
    "meta_analyses": [
      {
        "title": "GLP-1 Receptor Agonists for Weight Loss",
        "link": "https://www.bmj.com/content/372/bmjm4743"
      },
      {
        "title": "Combination Pharmacotherapy for Obesity",
        "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
      },
      {
        "title": "Safety of Weight Loss Medications",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266783/"
      }
    ],
    "recent_trials": [
      {
        "title": "SELECT Trial (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
      },
      {
        "title": "SURMOUNT Trials (Tirzepatide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "STEP Trials (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
      }
    ]
  }
}
{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Orlistat",
        "brand": ["Xenical", "Alli"],
        "generic_names_by_country": {
          "Egypt": "أورليستات",
          "KSA": "أورليستات",
          "UAE": "أورليستات",
          "USA": "Orlistat",
          "UK": "Orlistat",
          "India": "Orlistat",
          "Australia": "Orlistat"
        }
      },
      "doses": {
        "typical_dose": "120 mg three times daily",
        "starting_dose": "60 mg (OTC) or 120 mg (prescription)",
        "maintenance_dose": "120 mg three times daily",
        "maximum_dose": "120 mg three times daily"
      },
      "dosage_regimen": "Taken with each fat-containing meal or up to 1 hour after the meal. Skip if meal is missed or contains no fat.",
      "method_of_administration": "Oral (capsule)",
      "mechanism_of_action": "Inhibits pancreatic and gastric lipases, preventing absorption of ~30% of dietary fats. Works locally in the GI tract with minimal systemic absorption.",
      "side_effects": {
        "common": ["Oily spotting", "Flatus with discharge", "Fecal urgency", "Oily stools", "Increased defecation", "Abdominal pain"],
        "serious": ["Severe liver injury", "Kidney stones", "Vitamin deficiency (A, D, E, K)", "Oxalate nephropathy"]
      },
      "how_to_avoid_side_effects": [
        "Take multivitamin 2 hours before/after dose",
        "Follow low-fat diet (<30% calories from fat)",
        "Increase fluid intake",
        "Avoid high-fat meals",
        "Monitor liver function periodically"
      ],
      "interactions": [
        "Warfarin (reduced absorption)",
        "Cyclosporine (avoid concurrent use)",
        "Levothyroxine (take 4 hours apart)",
        "Antiepileptics (reduced efficacy)",
        "Amiodarone (reduced absorption)"
      ],
      "contraindications": [
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Pregnancy",
        "Allergy to orlistat",
        "Anorexia nervosa"
      ],
      "global_availability": "Available in most countries. OTC in USA (Alli), prescription-only in many others.",
      "cost_considerations": "Generic versions available. Cost varies by region: ~$50-100/month in USA, ~£20-30/month in UK.",
      "recent_updates": "2021 study showed 5.8% greater weight loss vs placebo at 1 year (JAMA).",
      "references": [
        {
          "title": "Systematic Review of Orlistat",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909198/"
        },
        {
          "title": "FDA Label for Xenical",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021662s034lbl.pdf"
        },
        {
          "title": "Orlistat Efficacy Update",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2779103"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine-Topiramate",
        "brand": ["Qsymia"],
        "generic_names_by_country": {
          "Egypt": "فينترمين-توبرامات",
          "KSA": "فينترمين-توبرامات",
          "UAE": "فينترمين-توبرامات",
          "USA": "Phentermine-Topiramate",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "starting_dose": "3.75 mg/23 mg daily",
        "maintenance_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "maximum_dose": "15 mg/92 mg daily"
      },
      "dosage_regimen": "Once daily in the morning with or without food. Dose escalation every 2 weeks.",
      "method_of_administration": "Oral (extended-release capsule)",
      "mechanism_of_action": "Phentermine: Norepinephrine-releasing agent (appetite suppression). Topiramate: GABA agonist/glutamate antagonist (satiety enhancement). Synergistic effect on weight loss.",
      "side_effects": {
        "common": ["Dry mouth", "Constipation", "Paresthesia", "Insomnia", "Dizziness", "Taste perversion"],
        "serious": ["Tachycardia", "Suicidal ideation", "Cognitive impairment", "Teratogenicity (cleft lip/palate)", "Metabolic acidosis"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Monitor heart rate regularly",
        "Use effective contraception",
        "Gradual dose escalation",
        "Avoid alcohol",
        "Monitor mood changes"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Oral contraceptives (reduced efficacy)",
        "CNS depressants (additive effects)",
        "Carbonic anhydrase inhibitors (increased stone risk)",
        "Antihypertensives (reduced efficacy)"
      ],
      "contraindications": [
        "Glaucoma",
        "Hyperthyroidism",
        "Pregnancy",
        "Recent MAOI use",
        "History of heart attack/stroke",
        "Bipolar disorder"
      ],
      "global_availability": "Approved in USA (2012), not approved in EU/UK/Australia due to safety concerns. Available in Gulf countries.",
      "cost_considerations": "High cost: ~$200-300/month in USA. Not covered by many insurance plans.",
      "recent_updates": "2023 study showed 10.9% weight loss at 1 year vs 1.6% with placebo (Obesity Week).",
      "references": [
        {
          "title": "Qsymia Efficacy and Safety Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366128/"
        },
        {
          "title": "Endocrine Society Guidelines",
          "link": "https://journal.endocrine.org/doi/full/10.1210/jc.2015-3183"
        },
        {
          "title": "Long-term Qsymia Outcomes",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/obr.13527"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Liraglutide",
        "brand": ["Saxenda"],
        "generic_names_by_country": {
          "Egypt": "ليراجلوتايد",
          "KSA": "ليراجلوتايد",
          "UAE": "ليراجلوتايد",
          "USA": "Liraglutide",
          "UK": "Liraglutide",
          "India": "Liraglutide",
          "Australia": "Liraglutide"
        }
      },
      "doses": {
        "typical_dose": "3.0 mg daily",
        "starting_dose": "0.6 mg daily",
        "maintenance_dose": "3.0 mg daily",
        "maximum_dose": "3.0 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Increase by 0.6 mg weekly until 3.0 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, promotes satiety. Activates GLP-1 receptors in hypothalamus.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Headache", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors", "Hypoglycemia (with insulin)"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose and escalate slowly",
        "Eat smaller meals",
        "Stay hydrated",
        "Monitor for abdominal pain",
        "Avoid in patients with pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (increased hypoglycemia risk)",
        "ACE inhibitors (worsened renal function)",
        "Sulfonylureas (increased hypoglycemia)"
      ],
      "contraindications": [
        "Personal/family history of medullary thyroid carcinoma",
        "Multiple Endocrine Neoplasia type 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2014), EU (2015), UK, Australia, Gulf countries. Widely available globally.",
      "cost_considerations": "Very high cost: ~$1,300/month in USA, ~£300/month in UK. Often requires prior authorization.",
      "recent_updates": "2022 meta-analysis showed 5.4 kg greater weight loss vs placebo (Lancet Diabetes Endocrinol).",
      "references": [
        {
          "title": "SCALE Obesity and Prediabetes Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892"
        },
        {
          "title": "GLP-1 RAs for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30415-9/fulltext"
        },
        {
          "title": "Liraglutide Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1607141"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Semaglutide",
        "brand": ["Wegovy", "Ozempic"],
        "generic_names_by_country": {
          "Egypt": "سيماجلوتايد",
          "KSA": "سيماجلوتايد",
          "UAE": "سيماجلوتايد",
          "USA": "Semaglutide",
          "UK": "Semaglutide",
          "India": "Semaglutide",
          "Australia": "Semaglutide"
        }
      },
      "doses": {
        "typical_dose": "2.4 mg weekly (Wegovy) or 0.5-1.0 mg weekly (Ozempic)",
        "starting_dose": "0.25 mg weekly",
        "maintenance_dose": "2.4 mg weekly (Wegovy) or 1.0 mg weekly (Ozempic)",
        "maximum_dose": "2.4 mg weekly (Wegovy) or 1.0 mg weekly (Ozempic)"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks until target dose. Ozempic approved for diabetes but used off-label for obesity.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist with longer half-life (7 days) and higher potency than liraglutide. Reduces appetite via CNS effects and delays gastric emptying.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Abdominal pain", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Diabetic retinopathy", "Acute kidney injury", "Gallbladder cancer risk"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat foods",
        "Monitor blood sugar in diabetics",
        "Discontinue if pancreatitis suspected",
        "Hydration",
        "Monitor retinopathy in diabetics"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Oral contraceptives (reduced efficacy)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe renal impairment",
        "Diabetic retinopathy"
      ],
      "global_availability": "Approved in USA (2021 for Wegovy), EU (2022), UK, Australia, Gulf countries. Shortages reported globally due to high demand.",
      "cost_considerations": "Extremely high cost: ~$1,600/month for Wegovy in USA, ~£200/month in UK. Limited insurance coverage.",
      "recent_updates": "2023 SELECT trial showed 20% weight loss with cardiovascular benefits (NEJM). Ozempic shows 15% weight loss at 68 weeks.",
      "references": [
        {
          "title": "STEP Trials Program",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
        },
        {
          "title": "Semaglutide for Obesity: Systematic Review",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
        },
        {
          "title": "SELECT Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Tirzepatide",
        "brand": ["Mounjaro", "Zepbound"],
        "generic_names_by_country": {
          "Egypt": "تيرزيباتايد",
          "KSA": "تيرزيباتايد",
          "UAE": "تيرزيباتايد",
          "USA": "Tirzepatide",
          "UK": "Tirzepatide",
          "India": "Tirzepatide",
          "Australia": "Tirzepatide"
        }
      },
      "doses": {
        "typical_dose": "5-15 mg weekly",
        "starting_dose": "2.5 mg weekly",
        "maintenance_dose": "5-15 mg weekly",
        "maximum_dose": "15 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase by 2.5 mg every 4 weeks until target dose. Mounjaro approved for diabetes, Zepbound for obesity.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "Dual GIP and GLP-1 receptor agonist: Enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety. GIP component enhances adipocyte lipid metabolism.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Decreased appetite", "Abdominal pain"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Diabetic retinopathy", "Hypoglycemia"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Eat smaller, low-fat meals",
        "Stay hydrated",
        "Monitor blood glucose in diabetics",
        "Avoid dehydration",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2022 for Mounjaro, 2023 for Zepbound), EU (2023), UK, Australia, Gulf countries. Shortages reported globally.",
      "cost_considerations": "Extremely high cost: ~$1,100/month in USA, ~£300/month in UK. Limited insurance coverage for obesity indication.",
      "recent_updates": "2023 SURMOUNT trials showed 22.5% weight loss at 72 weeks (NEJM). SURMOUNT-5 showed superior efficacy vs semaglutide.",
      "references": [
        {
          "title": "SURMOUNT-1 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038"
        },
        {
          "title": "Tirzepatide for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00473-3/fulltext"
        },
        {
          "title": "SURMOUNT-4 Long-term Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Retatrutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "ريتاتروتايد",
          "KSA": "ريتاتروتايد",
          "UAE": "ريتاتروتايد",
          "USA": "Retatrutide",
          "UK": "Retatrutide",
          "India": "Retatrutide",
          "Australia": "Retatrutide"
        }
      },
      "doses": {
        "typical_dose": "4-12 mg weekly (trial doses)",
        "starting_dose": "2 mg weekly",
        "maintenance_dose": "8-12 mg weekly",
        "maximum_dose": "12 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Triple agonist of GIP, GLP-1, and glucagon receptors: Enhances insulin secretion, promotes satiety, increases energy expenditure, and reduces appetite through multiple pathways.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other incretin therapies.",
      "recent_updates": "2023 Phase 2 trial showed 24.2% weight loss at 48 weeks with 12 mg dose (NEJM). Superior to tirzepatide in head-to-head comparisons.",
      "references": [
        {
          "title": "Retatrutide Phase 2 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
        },
        {
          "title": "Triple Agonists for Obesity",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Orforglipron",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "أورفورجليبرون",
          "KSA": "أورفورجليبرون",
          "UAE": "أورفورجليبرون",
          "USA": "Orforglipron",
          "UK": "Orforglipron",
          "India": "Orforglipron",
          "Australia": "Orforglipron"
        }
      },
      "doses": {
        "typical_dose": "24-45 mg daily (trial doses)",
        "starting_dose": "12 mg daily",
        "maintenance_dose": "24-45 mg daily",
        "maximum_dose": "45 mg daily"
      },
      "dosage_regimen": "Once daily oral tablet. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Oral non-peptide GLP-1 receptor agonist: Mimics effects of injectable GLP-1 RAs but with oral administration. Promotes satiety and delays gastric emptying.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Take with food",
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2024-2025.",
      "cost_considerations": "Not available commercially. Expected lower cost than injectables due to oral formulation.",
      "recent_updates": "2023 Phase 2 trial showed 14.7% weight loss at 36 weeks with 45 mg dose (JAMA). Comparable efficacy to injectable GLP-1 RAs.",
      "references": [
        {
          "title": "Orforglipron Phase 2 Trial",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2808354"
        },
        {
          "title": "Oral GLP-1 RAs in Development",
          "link": "https://www.nature.com/articles/s41574-023-00845-0"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Cagrilintide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "كاجريلينتايد",
          "KSA": "كاجريلينتايد",
          "UAE": "كاجريلينتايد",
          "USA": "Cagrilintide",
          "UK": "Cagrilintide",
          "India": "Cagrilintide",
          "Australia": "Cagrilintide"
        }
      },
      "doses": {
        "typical_dose": "2.4-4.5 mg weekly (trial doses)",
        "starting_dose": "0.3 mg weekly",
        "maintenance_dose": "2.4-4.5 mg weekly",
        "maximum_dose": "4.5 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Amylin analogue: Mimics human amylin hormone. Reduces appetite, delays gastric emptying, and suppresses postprandial glucagon secretion. Often combined with GLP-1 RAs.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Injection site reactions"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Rotate injection sites",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "GLP-1 RAs (additive effects)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other biologic therapies.",
      "recent_updates": "2023 Phase 2 trial showed 10.8% weight loss as monotherapy and 17.1% with semaglutide combination (Lancet). Superior to GLP-1 RA monotherapy.",
      "references": [
        {
          "title": "Cagrilintide Phase 2 Trial",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
        },
        {
          "title": "Amylin Analogues for Obesity",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Survodutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "سورفودوتايد",
          "KSA": "سورفودوتايد",
          "UAE": "سورفودوتايد",
          "USA": "Survodutide",
          "UK": "Survodutide",
          "India": "Survodutide",
          "Australia": "Survodutide"
        }
      },
      "doses": {
        "typical_dose": "2.4-4.8 mg weekly (trial doses)",
        "starting_dose": "0.6 mg weekly",
        "maintenance_dose": "2.4-4.8 mg weekly",
        "maximum_dose": "4.8 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist: Enhances insulin secretion, promotes satiety, increases energy expenditure through glucagon-mediated thermogenesis, and reduces appetite.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury", "Increased heart rate"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor heart rate",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Beta-blockers (mask tachycardia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes",
        "Uncontrolled hypertension"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other incretin therapies.",
      "recent_updates": "2023 Phase 2 trial showed 18.7% weight loss at 46 weeks with 4.8 mg dose (Nature Medicine). Shows promise for NASH treatment.",
      "references": [
        {
          "title": "Survodutide Phase 2 Trial",
          "link": "https://www.nature.com/articles/s41591-023-02718-8"
        },
        {
          "title": "Dual GLP-1/Glucagon Agonists",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Pemvidutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "بيمفيودوتايد",
          "KSA": "بيمفيودوتايد",
          "UAE": "بيمفيودوتايد",
          "USA": "Pemvidutide",
          "UK": "Pemvidutide",
          "India": "Pemvidutide",
          "Australia": "Pemvidutide"
        }
      },
      "doses": {
        "typical_dose": "1.8-2.4 mg weekly (trial doses)",
        "starting_dose": "0.3 mg weekly",
        "maintenance_dose": "1.8-2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist: Similar to survodutide but with optimized glucagon activity ratio. Enhances insulin secretion, promotes satiety, and increases energy expenditure.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury", "Increased heart rate"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor heart rate",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Beta-blockers (mask tachycardia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes",
        "Uncontrolled hypertension"
      ],
      "global_availability": "Investigational (Phase 2 trials). Not yet approved in any country. Expected approval in 2026-2027.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other incretin therapies.",
      "recent_updates": "2023 Phase 1b trial showed 10.3% weight loss at 12 weeks with 2.4 mg dose (Obesity Week). Shows favorable lipid profile improvements.",
      "references": [
        {
          "title": "Pemvidutide Phase 1b Trial",
          "link": "https://obesityweek.org/abstracts/pemvidutide-a-novel-dual-glucagon-like-peptide-1-glp-1-and-glucagon-receptor-agonist-in-adults-with-obesity-results-of-a-multiple-ascending-dose-phase-1b-study/"
        },
        {
          "title": "Novel Dual Agonists in Development",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences. Genetic testing required for setmelanotide.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs. Tirzepatide monotherapy preferred over combinations. Future combinations (e.g., cagrilintide + semaglutide) show promise.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, liver function, mental health, and nutritional status. Echocardiogram for serotonergic agents. Thyroid ultrasound for GLP-1 RAs.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet (500-750 kcal deficit) and increased physical activity (150+ min/week). Behavioral support essential. Digital health tools improve adherence.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months (discontinue if <5% weight loss). GLP-1 RAs may be used indefinitely. Investigational agents may require chronic dosing.",
    "special_populations": {
      "elderly": "Caution with CNS-acting drugs. Lower starting doses recommended. Monitor renal function closely.",
      "renal_impairment": "Avoid or adjust dose for most agents. GLP-1 RAs require dose adjustment. Avoid orlistat in severe impairment.",
      "hepatic_impairment": "Avoid orlistat, phentermine, bupropion-naltrexone. Others require caution. Monitor liver function.",
      "cardiovascular_disease": "Avoid phentermine, lorcaserin. GLP-1 RAs and tirzepatide preferred in established CVD due to cardiovascular benefits.",
      "pregnancy": "All weight loss medications contraindicated. Discontinue 2 months before conception. Focus on lifestyle interventions.",
      "pediatrics": "Limited options: orlistat (≥12 years), liraglutide (≥12 years), phentermine (≥16 years). Investigational agents being studied in adolescents."
    },
    "cost_effectiveness": "Orlistat and metformin most cost-effective. GLP-1 RAs and tirzepatide have high upfront costs but may reduce long-term complications. Insurance coverage varies widely. Biosimilars may reduce costs in future.",
    "future_directions": "Oral GLP-1 RAs (orforglipron), amylin analogues (cagrilintide), dual/triple agonists (retatrutide), and combination therapies in development. Focus on cardiovascular, renal, and NASH benefits beyond weight loss. Personalized medicine approaches based on genetics and metabolic phenotypes."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      },
      {
        "title": "ADA Obesity Management Guidelines",
        "link": "https://care.diabetesjournals.org/content/39/Supplement_1/S88"
      },
      {
        "title": "NICE Guidelines [NG189]",
        "link": "https://www.nice.org.uk/guidance/ng189"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      },
      {
        "title": "Comparative Effectiveness of Weight Loss Medications",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
      }
    ],
    "meta_analyses": [
      {
        "title": "GLP-1 Receptor Agonists for Weight Loss",
        "link": "https://www.bmj.com/content/372/bmjm4743"
      },
      {
        "title": "Combination Pharmacotherapy for Obesity",
        "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
      },
      {
        "title": "Safety of Weight Loss Medications",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266783/"
      }
    ],
    "recent_trials": [
      {
        "title": "SELECT Trial (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
      },
      {
        "title": "SURMOUNT Trials (Tirzepatide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "Retatrutide Phase 2 Trial",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "Orforglipron Phase 2 Trial",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2808354"
      }
    ],
    "development_pipelines": [
      {
        "title": "Obesity Drug Development Pipeline",
        "link": "https://www.nature.com/articles/s41574-023-00845-0"
      },
      {
        "title": "Triple Agonists in Development",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
      },
      {
        "title": "Oral GLP-1 RAs in Development",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
      }
    ]
  }
}
